- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ajanta Pharma's board approved Q1 FY27 consolidated results: Revenue at ₹1,626 Cr (up 25%) and PAT at ₹334 Cr (up 31%). The company also declared an interim dividend of ₹32 per share, totaling ₹400 Cr.